A new FDA pilot program to quickly advance gene therapies for rare diseases will use several elements of the Operation Warp Speed medical product development program for COVID-19 products, said CBER Director Peter Marks at the FDA Regulatory Education for Industry (REdI) Annual Conference on Monday.
Source: Drug Industry Daily